EGF-coated gold nanoparticles provide an efficient nano-scale delivery system for the molecular radiotherapy of EGFR-positive cancer

Abstract

Purpose Radiolabeled antibodies and peptides hold promise for molecular radiotherapy but are often limited by a low payload resulting in inadequate delivery of radioactivity to tumour tissue and, therefore, modest therapeutic effect. We developed a facile synthetic method of radiolabeling indium-111 (¹¹¹In) to epidermal growth factor (EGF)-gold nanoparticles (¹¹¹In-EGF-Au NP) with a high payload.

Materials and methods EGF-Au NP were prepared via an interaction between gold and the disulphide bonds of EGF and radiolabeled using ¹¹¹InCl₃. Targeting efficiency was investigated by quantitating internalized radioactivity and by confocal imaging following exposure of MDA-MB-468 (1.3 × 10⁶ EGFR/cell) and MCF-7 (10⁴ EGFR/cell) cells to Cy3-EGF-Au NP. Cytotoxicity was evaluated in clonogenic assays.

Results The proportion of total administered radioactivity that was internalized by MDA-MB-468 and MCF-7 cells was 15% and 1.3%, respectively (mixing ratio of EGF:Au of 160). This differential uptake in the two cell lines was confirmed using confocal microscopy. ¹¹¹In-EGF-Au NP were significantly more radiotoxic to MDA-MB-468 than MCF-7 cells with a surviving fraction of 17.1 ± 4.4% versus 89.8 ± 1.4% (p < 0.001) after exposure for 4 h.

Conclusions An ¹¹¹In-labeled EGF-Au nanosystem was developed. It enabled targeted delivery of a high ¹¹¹In payload specifically to EGFR-positive cancer cells leading to radiotoxicity that can be exploited for molecularly targeted radiotherapy.

Keywords:

• Gold nanoparticles
• Auger electron emitters
• EGF
• Indium-111
• targeted radiotherapy

Acknowledgements

This work was supported by Cancer Research UK [grant number C5255/A15935], the Medical Research Council and the CR-UK Oxford Cancer Imaging Centre.

Disclosure statement

The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper.